S-1/A: Elevai Labs Inc. Eyes Public Offering to Bolster Growth and Nasdaq Compliance

Elevai Labs Inc. is seeking to raise capital through a public offering of common stock and warrants to fund general corporate purposes and maintain Nasdaq compliance.

Summary

• Elevai Labs Inc. is planning a public offering involving shares of common stock, pre-funded warrants, Series A warrants, and Series B warrants.
• The company intends to use the net proceeds for general corporate purposes, including working capital and investments.
• The offering includes up to 28,368,794 shares of common stock, Series A warrants to purchase up to 28,368,794 shares, and Series B warrants to purchase up to 28,368,794 shares.
• Each share of common stock, or a pre-funded warrant in lieu thereof, is being sold together with a Series A Warrant and a Series B Warrant.
• The assumed public offering price is $0.282 per share, based on the last reported sale price on September 10, 2024.
• The Series A Warrants will have an exercise price of at least 250% of the Minimum Price as defined by Nasdaq and expire five years after the Initial Exercise Date.
• The Series B Warrants will have an exercise price of at least 250% of the Minimum Price as defined by Nasdaq and expire two and one-half years after the Initial Exercise Date.
• The offering also includes pre-funded warrants for purchasers whose ownership would exceed 4.99% of the outstanding common stock, with an exercise price of $0.0001 per share.
• Univest Securities, LLC is acting as the exclusive placement agent for the offering.
• The offering is expected to close around September 24, 2024, and there is no minimum offering requirement.
• The selling stockholders are also offering an aggregate of 1,299,999 shares of common stock through a separate resale prospectus.
• The company is an emerging growth company and a smaller reporting company, which allows for certain reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as ongoing research and development and potential market growth, the company faces significant financial challenges, regulatory hurdles, and competitive pressures, leading to an overall cautious outlook.

Positives

• The company is expanding its marketing efforts and pursuing an e-commerce sales model.
• Elevai Biosciences Inc. is developing EL-22, an engineered probiotic to address muscle loss during weight loss treatments.
• Elevai Research Inc. has a stem cell exosome research partnership with Dalhousie University and a grant from Mitacs.
• The company has a proprietary process called Precision Regenerative Exosome Technology (PREx) for exosome production.
• The company has established partnerships with major industry players and local universities.
• The company has a well-recognized and award-winning team and brand.

Negatives

• The company has a history of net losses and may not be able to achieve or maintain profitability.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may sell fewer than all of the securities offered, which will provide limited working capital.
• The company has suspended sales in Canada due to regulatory issues.
• The company may not be able to continue to satisfy listing requirements of Nasdaq to maintain a listing of its common stock.

Risks

• The company's revenues depend significantly on sales of its Elevai Post Treatment E-Series.
• The company faces intense competition from companies with greater resources.
• The company's products could be rendered obsolete by technological or medical advances.
• The company depends on collaborators to develop and test its products, and collaborations may be unsuccessful.
• The company may be subject to product liability claims.
• The company may be unable to protect its proprietary technology.
• The company may need additional capital and may be unable to obtain it on satisfactory terms.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company intends to focus on growing revenue, utilizing clinical validation studies, conducting R&D, pursuing acquisitions, and considering potential spin-offs.

Industry Context

The announcement relates to the medical aesthetics and biopharmaceutical sectors, specifically focusing on skincare and obesity treatments, which are growing markets with increasing consumer demand.

Comparison to Industry Standards

• The skincare segment within the physician-dispensed market is projected to grow by a 9.6% CAGR to reach $37.3 billion by 2030.
• The global physician-dispensed cosmeceuticals market is projected to reach $19.08 billion by 2031, growing at a CAGR of 8.98% from 2024.
• Approved GLP-1 drugs used in weight loss, such as Novo Nordisks Ozempic and Wegovy and Eli Lillys Zepbound and Mounjaro have transformed the obesity treatment landscape.
• However, past studies of these highly effective drugs show that up to 20-50% of the weight loss is due to loss of lean muscle.
• Several key companies are actively developing GLP-1 drugs for obesity and complementary treatments to address associated conditions such as muscle wasting: Versanis, Biohaven, Scholar Rock, Keros, and Veru.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Shareholders may be impacted by the company's ability to maintain Nasdaq listing.
• Employees may be impacted by the company's restructuring and reduction in force.
• Customers may be impacted by the company's ability to maintain product quality and availability.

Next Steps

• The company intends to file the Split Amendment and the Increase in Authorized Shares Amendment and effect the reverse stock split and increase the total number of authorized shares as soon as permitted pursuant to the rules of the SEC.
• The Company intends to complete an IND submission in 2025 and to initiate clinical trials in the U.S. to evaluate the myostatin approach in combination with one or more GLP-1 receptor agonists in obesity.

Key Dates

Keywords

Elevai Labs, public offering, common stock, warrants, exosomes, skincare, biopharmaceutical, Nasdaq, EL-22, EL-32, PREx, hUMSCs, medical aesthetics, Univest Securities, emerging growth company, smaller reporting company